Program
Saccharomyces cerevisiae
Also written as “Saccharomyces Boulardii 250 MG”, “Probiotic : Saccharomyces boulardii” and “Saccharomyces boulardii”.
Its studies are mostly in Irritable Bowel Syndrome · Gastroenteritis · Diarrhea, led by Biocodex.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biocodex | 31 open or running | phase 4since May 16, 2018 | Nov 2, 1999 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 2 study in DiarrheaFirst studyNCT00002088 · 100 enrolled · United States
- May 16, 2018Phase 4 study in Acute GastroenteritisNCT03539913 · 317 enrolled · Argentina
- Aug 22, 2025Phase 3 study in Irritable Bowel SyndromeNCT07168434 · 406 planned · Portugal, Spain
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07168434Irritable Bowel Syndrome · Portugal, Spain | 3 | Recruiting | Oct 11, 2026 | 406 |
| NCT03539913Acute Gastroenteritis · Argentina | 4 | Completed | Jun 9, 2018 | 317 |
| NCT00002088Diarrhea · United States | 2 | Completed | 100 |
How it is read
Names in the registry
- “Saccharomyces Boulardii 250 MG”, 1 entry
- “Probiotic : Saccharomyces boulardii”, 1 entry
- “Saccharomyces boulardii”, 1 entry
Conditions, from the studies’ own filings
- Irritable Bowel Syndrome, 1 study
- Gastroenteritis, 1 study
- Diarrhea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.